Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis

Table 3 Subgroup analysis of SVR12 for GT1

Response	GT1 (N = 1076)		Heterogeneity		P^b-value	Studies
	Total, n/N	Rate (95%CI)	I²(%)	P ^a
Overall	1025/1076	96.2 (94.8–97.4)	38	0.13		10
By the different duration of treatment					0.9668
12 weeks	364/384	96.2 (92.5–98.9)	38	0.15		6
24 weeks	52/55	96.6 (82.5–100.0)	65	0.09		2
By regimens					0.8742
OBV/PTV/r + DSV	163/170	97.0 (93.3–99.5)	0	0.41		4
OBV/PTV/r + DSV + RBV	350/368	95.8 (91.6–98.8)	56	0.06		5
By genotypes					0.6031
1a	583/608	96.2 (94.5–97.7)	49	0.10		5
1b	311/326	95.9 (93.3–98.0)	14	0.33		5
By treatment history					0.6859
TN patients	407/423	96.9 (94.9–98.5)	41	0.15		5
TE patients	262/274	98.7 (96.1–100.0)	46	0.12		5
By the presence or absence of cirrhosis					0.2581
Cirrhosis	207/219	97.6 (94.2–99.7)	45	0.11		6
Non-cirrhosis	753/781	96.9 (95.5–98.2)	20	0.28		6
By baseline HCV RNA					0.3939
<6 log10 IU/m L	293/304	97.0 (87.8–100.0)	89	<0.01		3
≥6 log10 IU/m L	160/171	94.0 (89.6–97.4)	0	0.87		3
By CD4 cell counts/mm³					0.7810
≤500	129/132	97.8 (94.2–99.8)	0	0.71		2
>500	246/254	96.9 (94.3–98.8)	0	0.38		2
Platelet counts/μL					0.7925
≤100,000	37/38	98.2 (89.8–100.0)	0	0.41		2
>100,000	338/348	97.2 (95.1–98.7)	0	0.38		2
By IL 28B genotype^c					0.9685
CC	37/38	97.4 (89.0–100.0)	–	–		1
Non-CC	101/105	97.9 (93.3–100.0)	71	0.06		2

*OBV ombitasvir, PTV paritaprevir, r ritonavir, DSV dasabuvir, RBV ribavirin, GT genotype, TN treatment-naive, TE treatment-experienced, CI confidence interval
^aTest of heterogeneity
^bTest for subgroup differences
^cOnly one article had the SVR rate of IL 28B CC genotype, thus, there were no test of heterogeneity for it

ISSN: 1743-422X